Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.44 |
| ▸ | GUSB | P08236 | 2/20 | 0.35 |
| ▸ | EBP | Q15125 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 4/20 | 0.34 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | DRD1 | P21728 | 3/20 | 0.34 |
| ▸ | DRD4 | P21917 | 3/20 | 0.34 |
| ▸ | DRD5 | P21918 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26280366 | 0.96 | BCHE (0.40) | BCHEEPHX1DRD3HTR1ADRD1 | |
| SCHEMBL23559964 | 0.96 | BCHE (0.40) | BCHEEPHX1DRD3HTR1ADRD1 | |
| SCHEMBL24379958 | 0.91 | DRD3 (0.41) | BCHEDRD3 | |
| SCHEMBL26406909 | 0.87 | BCHE (0.43) | BCHEEBPSIGMAR1EPHX1DRD3 | |
| SCHEMBL22837769 | 0.86 | BCHE (0.42) | BCHEGUSBEBPSIGMAR1EPHX1 | |
| SCHEMBL25122901 | 0.86 | BCHE (0.42) | BCHEGUSBEBPSIGMAR1EPHX1 | |
| SCHEMBL25729879 | 0.86 | BCHE (0.42) | BCHEGUSBEBPSIGMAR1EPHX1 | |
| SCHEMBL25925738 | 0.86 | OPRL1 (0.33) | BCHE | |
| SCHEMBL25925770 | 0.86 | OPRL1 (0.33) | BCHE | |
| SCHEMBL22856498 | 0.85 | CCR2 (0.41) | DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | BCHE 2634/4885GUSB 1746/4885EBP 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.